THE IMPACT OF THE FDA'S RISK EVALUATION AND MITIGATION STRATEGIES (REMS) INITIATIVE ON PRESCRIPTION PATTERN FOR DRUGS APPROVED UNDER THE REMS PROGRAM AND RELEVANT NON-REMS COMPETITORS

被引:0
作者
Horowicz-Mehler, N. [1 ]
Sepulveda, B. [1 ]
White, C. [1 ]
Doyle, J. [1 ]
机构
[1] Quintiles Global Consulting, Hawthorne, NY USA
关键词
D O I
10.1016/S1098-3015(10)72993-4
中图分类号
F [经济];
学科分类号
02 ;
摘要
引用
收藏
页码:A203 / A203
页数:1
相关论文
empty
未找到相关数据